Stock Research for XOMA


Featured Broker: Ally Invest

Get the due diligence for another stock.


XOMA Stock Chart & Research Data

The XOMA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the XOMA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


XOMA Due diligence Resources & Stock Charts

The XOMA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View XOMA Detailed Price Forecast - CNN Money CNN View XOMA Detailed Summary - Google Finance
Yahoo View XOMA Detailed Summary - Yahoo! Finance Zacks View XOMA Stock Research & Analysis -

Stock Analysis

TradeIdeas View XOMA Trends & Analysis - Trade-Ideas Barrons View XOMA Major Holders - Barrons
NASDAQ View XOMA Call Transcripts - NASDAQ Seeking View XOMA Breaking News & Analysis - Seeking Alpha
Spotlight View XOMA Annual Report - OTC Report View XOMA OTC Short Report -
TradeKing View XOMA Fundamentals - TradeKing Charts View XOMA SEC Filings - Bar Chart
WSJ View Historical Prices for XOMA - The WSJ Morningstar View Performance/Total Return for XOMA - Morningstar
MarketWatch View the Analyst Estimates for XOMA - MarketWatch CNBC View the Earnings History for XOMA - CNBC
StockMarketWatch View the XOMA Earnings - StockMarketWatch MacroAxis View XOMA Buy or Sell Recommendations - MacroAxis
Bullish View the XOMA Bullish Patterns - American Bulls Short Pains View XOMA Short Pain Metrics -

Social Media Mentions

StockTwits View XOMA Stock Mentions - StockTwits PennyStocks View XOMA Stock Mentions - PennyStockTweets
Twitter View XOMA Stock Mentions - Twitter Invest Hub View XOMA Investment Forum News - Investor Hub
Yahoo View XOMA Stock Mentions - Yahoo! Message Board Seeking Alpha View XOMA Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for XOMA - Insider Cow View Insider Transactions for XOMA - Insider Cow
CNBC View XOMA Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for XOMA - OTC Markets
Yahoo View Insider Transactions for XOMA - Yahoo! Finance NASDAQ View Institutional Holdings for XOMA - NASDAQ

Stock Charts

FinViz View XOMA Stock Insight & Charts - StockCharts View XOMA Investment Charts -
BarChart View XOMA Stock Overview & Charts - BarChart Trading View View XOMA User Generated Charts - Trading View

Latest Financial News for XOMA

XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights
Posted on Thursday March 07, 2019

Added seven new partner-funded programs in 2018 with potential for milestone and royalty paymentsCurrent cash balance sufficient to fund operations for multiple years.

XOMA to Present at the Cowen and Company 39th Annual Health Care Conference
Posted on Tuesday March 05, 2019

XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts.  The presentation will take place on Tuesday, March 12, 2019, at 12:00PM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at  An archived version of the webcast will be available for 90 days after the event. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future.  For more information, visit

XOMA Receives $5.5 Million Payment from Rezolute
Posted on Wednesday February 13, 2019

XOMA Corporation (XOMA) announced today it has received a $5.5 million payment from Rezolute, Inc., related to the Companies’ 2017 license agreement, as most recently amended on January 7, 2019. “Our business model is fundamentally designed to generate significant long-term royalty-based revenue as the underlying assets are commercialized.  Moreover, many of our license agreements include the potential for XOMA to receive significant milestone payments as the licensed assets progress.  The receipt of this milestone payment is a good example of XOMA further strengthening its balance sheet with additional non-dilutive capital.  This capital can be deployed to further expand our portfolio of assets from which we have the potential to earn future milestone payments and royalties,” commented Jim Neal, Chief Executive Officer at XOMA.

How Much Are XOMA Corporation (NASDAQ:XOMA) Insiders Spending On Buying Shares?
Posted on Monday February 04, 2019

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many times Read More...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.